logo-loader
viewOptiBiotix Health PLC

OptiBiotix Health - Launch of weight management products

RNS Number : 6922B
OptiBiotix Health PLC
12 October 2020
 

OptiBiotix Health plc

("OptiBiotix" or the "Company")

 

Launch of weight management products in Australia and New Zealand

Shakes and bars containing OptiBiome® technology

 

OptiBiotix Health plc (AIM: OPTI), a life sciences business developing compounds to tackle obesity, high cholesterol, diabetes and skincare, announces the launch of meal replacement shakes and bars containing OptiBiotix's OptiBiome® proprietary weight management technology under the Optislim® brand with Woolworths, ChemistWarehouse and on OptiPharm Pty Ltd's ("OptiPharm") online store in Australia and New Zealand.

 

These simultaneous launches build on a licence agreement entered into in March 2020 granting OptiPharm exclusive use of the OptiBiome® trademark in Australia, parts of Asia, New Zealand, Middle East, the Gulf States and North America (RNS: 31 March 2020) and subsequent extension of terms to include Europe (RNS: 5 August 2020).

 

OptiPharm is a privately owned Australian company which has been operating for 24 years. OptiPharm's flagship brand, Optislim®, is the No. 1 Australian weight management brand incorporating shakes, soups and bars available as total (very low calorie diet) or partial (low calorie diet) meal replacements. 

 

Garry McDonald, Managing Director of OptiPharm, commented: "We are delighted to announce the release of our Optislim® - Optibiome® range of meal replacement shakes & snack bars. Products will be available to Australian consumers from the week commencing 12 October 2020 via the Chemist Warehouse group and the Woolworths supermarket chain. Release will follow shortly throughout New Zealand with contracts currently being finalised for a number of regions throughout Asia. Essentially, we are revolutionising meal replacements utilising OptiBiome®, the award winning, patented ingredient from OptiBiotix. We look forward to a long and successful association with the OptiBiotix team."

 

Dr. Fred Narbel, Managing Director of OptiBiotix's prebiotics division, commented: "We are very pleased to announce the commercial launch of these weight management products containing OptiBiome® under OptiPharm's Optislim® brand. OptiBiotix's partnership with Australia's No. 1 weight management brand combined with the retailers' distribution network allows the Company to access a wide base of customers in Australia and New Zealand and provide them with a scientifically proven and award-winning ingredient to help them achieve their weight loss. This first commercial step with OptiPharm highlights the strength of the relationship between the two companies and we look forward to future commercial launches beyond Australia and New Zealand."

 

This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014.

 

For further information, please contact:

 

OptiBiotix Health plc

www.optibiotix.com

Stephen O'Hara, Chief Executive

Contact via Walbrook below

 

 

Cairn Financial Advisers LLP (NOMAD)

Tel: 020 7213 0880

Liam Murray / Jo Turner / Ludovico Lazzaretti

 

 

 

finnCap (Broker)

Tel: 020 7220 0500

Geoff Nash / Kate Bannatyne (Corporate Finance)

 

 

 

Walbrook PR Ltd

Mob: 07876 741 001

Anna Dunphy

 

     

 

 

About OptiBiotix - www.optibiotix.com 

OptiBiotix Health plc (AIM: OPTI), which was formed in March 2012, brings science to the development of compounds which modify the human microbiome - the collective genome of the microbes in the body - in order to prevent and manage human disease and promote wellness. 

 

OptiBiotix has an extensive R&D programme working with leading academics in the development of microbial strains, compounds, and formulations which are used as active ingredients and supplements. More than twenty international food and healthcare supplement companies have signed agreements with OptiBiotix to incorporate their human microbiome modulators into a wide range of food products and drinks.

 

OptiBiotix is also developing its own range of consumer supplements, and health snacks and food  products. The Company's current areas of focus include obesity, digestive health, cardiovascular health, and diabetes. 

 

 

Caution regarding forward looking statements

Certain statements in this announcement, are, or may be deemed to be, forward looking statements. Forward looking statements are identified by their use of terms and phrases such as ''believe'', ''could'', "should" ''envisage'', ''estimate'', ''intend'', ''may'', ''plan'', ''potentially'', "expect", ''will'' or the negative of those, variations or comparable expressions, including references to assumptions. These forward looking statements are not based on historical facts but rather on the Directors' current expectations and assumptions regarding OptiBiotix's future growth, results of operations, performance, future capital and other expenditures (including the amount, nature and sources of funding thereof), competitive advantages, business prospects and opportunities. Such forward looking statements reflect the Directors' current beliefs and assumptions and are based on information currently available to the Directors.

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
PRLFLFFEILLAIII

Quick facts: OptiBiotix Health PLC

Price: 51

Market: AIM
Market Cap: £44.85 m
Follow

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Market report: UK awaits Westminsters' three-tier local lockdown system

FTSE 100 opened lower as it nervously awaits Westminster’s announcement on the three-tier local lockdown system scheduled for today. British Airways is replacing chief executive Alex Cruz with Aer Lingus boss Sean Doyle. Cruz was criticised by politicians and trade unions after cutting 10,700...

on 12/10/20